Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
Jessica HarrisKoen B PouwelsThomas W JohnsonJonathan A C SterneChristalla Pithara-McKeownKalaivani MahadevanBarnaby C ReevesUmberto BenedettoYoon Kong LokeDaniel S LassersonBrett DobleNoreen Hopewell-KellySabi RedwoodSarah WordsworthAndrew D MumfordChris A RogersMaria PufuletePublished in: Health technology assessment (Winchester, England) (2023)
; Vol. 27, No. 8. See the NIHR Journals Library website for further project information.
Keyphrases
- antiplatelet therapy
- end stage renal disease
- acute coronary syndrome
- percutaneous coronary intervention
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- atrial fibrillation
- healthcare
- randomized controlled trial
- bone marrow
- mesenchymal stem cells
- cell therapy
- transcatheter aortic valve replacement
- smoking cessation